David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
David Sinclair plans human tests of an oral reprogramming drug for XPrize’s healthspan contest. The work aims at age restoration, and Sinclair says his lab is starting to use AI to improve the compounds.
Intelligence analysis by GPT-5.4 Mini
MIT Technology Review reports that David Sinclair wants to take epigenetic reprogramming beyond eye-only gene therapy and into oral drugs for whole-body rejuvenation. The effort is tied to XPrize’s $101 million healthspan competition and backed by ongoing animal studies and early human trial plans.
David Sinclair wants to see if a medicine people can swallow could help body cells act younger, like giving an old phone a new battery. It is part of a big contest, and AI may help his team adjust the recipe faster.
Analysis
What Sinclair is trying to do
David Sinclair is planning human tests of an oral “reprogramming” drug as part of XPrize’s Healthspan Competition. The goal is not just to treat a single organ, but to see whether a drug can help restore signs of youth across the body, measured by improvements in immune, cognitive, and muscle function.
The article says the competition’s top award goes to teams that can show a 10-year or greater relative improvement after one year of treatment. Sinclair told MIT Technology Review that he wants to give volunteers an oral drug mixture in search of “evidence for age restoration in humans.”
Why this is different
The broader scientific idea is epigenetic reprogramming, which comes from the discovery that certain genes can turn mature cells into stem-cell-like cells. The hoped-for effect is that resetting epigenetic marks may restore some youthful cell behavior. Sinclair’s newer plan is bolder than Life Biosciences’ eye-focused gene therapy trial: it aims for a drug people could swallow, rather than a complex gene treatment limited to the eyes.
Sinclair declined to identify the exact drug, code-named SL-100, but said the contents are confidential. The article notes that his previous patents and lab work used mixes of supplements, approved medicines, and experimental compounds. James Clement of Betterhumans said in a message that his group is running clinical trials for Sinclair’s XPrize team.
The AI angle
Sinclair says his lab is beginning to use AI to improve the oral agents under test. That suggests AI is being used as a tool to help optimize drug mixtures in a field where the chemistry is complex and the biological targets are still uncertain.
Risks and uncertainty
Several experts quoted in the article are cautious. They note that chemical reprogramming, as used in labs, often relies on very high concentrations and may be harsh or weak in practice. The article also makes clear that the competition is still early, with finalists still being selected and human testing requirements only now coming into view.
Key points
- Sinclair plans human tests of an oral reprogramming drug for XPrize’s healthspan competition.
- The competition rewards teams that can restore signs of youth in immune, cognitive, and muscle function.
- Sinclair says his lab is starting to use AI to improve the oral agents being tested.
- Experts quoted in the article warn that chemical reprogramming can be harsh and may not work well in practice.
- The effort is part of a wider race to turn epigenetic reprogramming into a rejuvenation therapy.
If the approach works, it could point to a practical way to test age-restoring drugs across the body instead of only in one organ. The article also suggests AI could help refine the drug mix faster, which may speed up progress in a hard-to-solve area of medicine.
The article makes clear that chemical reprogramming is still experimental and can be harsh in lab settings. Even with AI help, the drug may prove too weak, too risky, or too uncertain to produce the kind of human age-restoration effect the competition wants.
